Venture Challenge Alumnus of 2010 NTRC Therapeutics closes deal with Symeres and sells CRO division Oncolines B.V

Oncolines B.V., the CRO division of NTRC B.V. has been acquired by Symeres.

NTRC Therapeutics participated in the Venture Challenge of 2010. The team consisted of Guido Zaman and Rogier Buijsman. They specialize in new compounds for cancer therapy.

Oncolines B.V. is a precision medicine services company in oncology and cancer immunotherapy. They help to bring improved and novel therapies to the right patient population faster. They offer services to characterize compounds, and to determine activities, selectivities and mechanism of action.

Symeres is a transatlantic small molecule contract research and manufacturing organization for biotech and pharma companies for over 30 years.

Read all about the acqusition in the FD.